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RESEARCH ARTICLE
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With Orthotopic Triple-Negative Breast Cancer
Patient-Derived Tumor Xenografts
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ABSTRACT
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(T2W), radiofrequency (RF), repetition time (TR), signal-to-noise ratio (SNR), echo time (TE), field of
view (FOV), flip angle (FA), area under the time-course curve (AUC), standard deviations (SDs)

Preclinical imaging is critical in the development of translational strategies to detect diseases and monitor
response to therapy. The National Cancer Institute Co-Clinical Imaging Resource Program was launched, in
part, to develop best practices in preclinical imaging. In this context, the objective of this work was to develop a 1-hour, multiparametric magnetic resonance image-acquisition pipeline with triple-negative breast
cancer patient-derived xenografts (PDXs). The 1-hour, image-acquisition pipeline includes T1- and T2weighted scans, quantitative T1, T2, and apparent diffusion coefficient (ADC) parameter maps, and dynamic
contrast-enhanced (DCE) time-course images. Quality-control measures used phantoms. The triple-negative
breast cancer PDXs used for this study averaged 174 ⫾ 73 L in volume, with region of interest–averaged
T1, T2, and ADC values of 1.9 ⫾ 0.2 seconds, 62 ⫾ 3 milliseconds, and 0.71 ⫾ 0.06 m2/ms (mean ⫾
SD), respectively. Specific focus was on assessing the within-subject test–retest coefficient-of-variation (CVWS)
for each of the magnetic resonance imaging metrics. Determination of PDX volume via manually drawn regions of interest is highly robust, with ⬃1% CVWS. Determination of T2 is also robust with a ⬃3% CVWS.
Measurements of T1 and ADC are less robust with CVWS values in the 6%–11% range. Preliminary DCE test–retest time-course determinations, as quantified by area under the curve and Ktrans from 2-compartment exchange (extended Tofts) modeling, suggest that DCE is the least robust protocol, with ⬃30%– 40% CVWS.

INTRODUCTION
Triple-negative breast cancer (TNBC) is an aggressive tumor
characterized by poor outcomes and higher relapse rates compared with other subtypes of breast cancer. Pathologic complete
response often serves as an important endpoint in the treatment
of TNBC following neoadjuvant chemotherapy. It is critical to
identify patients who will respond to neoadjuvant chemotherapy
and, thus, avoid the use of ineffective treatments in nonresponding
patients. Toward that end, advanced quantitative imaging (QI)
strategies have been developed and evaluated for predicting or
assessing response to therapy in breast cancer. Although significant progress has been made in advancing such QI approaches,
preclinical imaging remains a critical component in the translational pipeline of validating advanced QI methods for applications
in drug discovery and assessment of response to therapy.

It is well appreciated that established tumor cell lines fail to
fully recapitulate the microstructural/environmental, cellular,
molecular, genetic and epigenetic properties, including abnormal vasculature with higher blood-vessel permeability, found in
clinical TNBC tumors (1). To that end, patient-derived tumor
xenografts (PDXs) are considered to provide more faithful tumor
models than traditional orthotopic implantation of established
tumor cell lines. The use of PDXs also ushers in new paradigms
involving coclinical trials in which QI applied to PDXs can be
implemented in the corresponding patient in a clinical setting
and vice versa. However, there are challenges in developing
optimal quantitative pipelines to assess response to therapy in a
preclinical setting. Most preclinical (small-animal) magnetic
resonance imaging (MRI) studies of cancer models involve tumor-cell implantation into the brain or leg (thigh) of the subject

© 2019 The Authors. Published by Grapho Publications, LLC This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ISSN 2379-1381 https://doi.org/10.18383/j.tom.2019.00012

320

TOMOGRAPHY.ORG

|

VOLUME 5

NUMBER 3

|

SEPTEMBER 2019

Multiparametric MRI Test–Retest Reproducibility With TNBC PDX

[see, for example (2-5)], which can be readily secured in the
small-animal bed/cradle of the scanner, thus minimizing artifacts caused by respiratory motion. However, in light of the
significance of the tumor microenvironment in tumor growth
and pathogenesis following cell implantation, it is relevant
that TNBC PDXs be implanted into mammary fat pads, which
are more susceptible to respiratory motion–related imaging
artifacts.
Recognizing the challenges of preclinical imaging using
realistic models of cancer, the National Cancer Institute recently
launched the Co-Clinical Imaging Resource Program to develop
best practices in preclinical imaging and support clinical trials.
In this context, the objective of this work was to develop and
implement a 1-hour, multiparametric MRI acquisition pipeline
with orthotopic TNBC PDXs. Tumor cells were implanted into
the fourth (inguinal/abdominal) mammary fat pad of NSGTM
mice and characterized by a pipeline of preclinical MRI experiments that included T1-weighted (T1W) and T2-weighted (T2W)
scans, quantitative T1, T2, and apparent diffusion coefficient
(ADC) parametric maps, and a dynamic contrast-enhanced
(DCE) protocol.
Conceptually, the project progressed through 3 stages:
(1) the precision and accuracy of the MRI acquisition pipeline’s
protocols were assessed via phantoms with known MR properties; (2) artifacts from respiratory motion were suppressed by
paying careful attention to mouse handling/placement within
the scanner’s cradle/bed, and, finally (3) the in vivo test–retest
reproducibility (precision) of MRI metrics was determined with
orthotopic TNBC PDXs.
METHODS
Generation of TNBC PDX

TNBC PDX. Tumors were generated in collaboration with the
Human and Mouse-Linked Evaluation of Tumors (HAMLET)
core of the Washington University School of Medicine’s Institute
of Clinical and Translational Sciences (http://digitalcommons.
wustl.edu/hamlet/). Details regarding animals, surgeries, and
tumor xenografts may be found in the report by Li et al. (6). All
animal experiments were conducted in compliance with the
Guidelines for the Care and Use of Research Animals established
by Washington University’s Institutional Animal Care and Use
Committee.
Experiments used NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD/
SCID) female mice obtained from The Jackson Laboratory (Bar
Harbor, ME). Mouse mammary fat pads were humanized as
previously described (7). Tumor samples from patients with
breast cancer were placed in ice-chilled DMEM/F12 medium,
necrotic tissue and fat were removed, and the samples were cut
into 1- ⫻ 1-mm2 pieces. Tissue fragments were engrafted into
the mammary glands. When xenograft tumors reached 1.5 cm in
diameter, they were harvested and dissociated into a single-cell
suspension.
Implantation of breast cancer cells used an inverted Y-shaped
incision along the thoracic–inguinal region to expose the mammary glands. Two-to-4 million tumor cells mixed with Matrigel
in a volume of 30 L were injected into the fourth inguinal
mammary fat pad. The skin was gathered, and the incision
closed with wound clips. Following engraftment, tumor growth
was monitored by means of calipers.
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MRI Scanner and RF Coil Configuration

All experiments were performed on an Agilent/Varian (Santa
Clara, CA) DirectDrive 4.7-T small-animal MR scanner built
around an Oxford Instruments (Abingdon, UK) horizontal superconducting magnet, with a gradient/shim coil assembly having a 12-cm inner-bore diameter and providing 60 G/cm with
200-s rise time. All MR images, including phantoms, were
acquired using the same laboratory-built actively decoupled
transmit (volume, 7.5-cm inner diameter) and receive (surface,
2.5-cm inner diameter) coil pair (8).
Homogeneous Aqueous Phantoms

Phantoms composed of homogeneous aqueous solutions, doped
with various amounts of manganese chloride (9) to span the T1
and T2 values encountered in vivo, were used to set pulse
sequence parameters and quantify performance under ideal
conditions.
Six-Compartment Variable Relaxation Phantom. A 6-compartment phantom was used to bridge the nominal range of in
vivo T1 and T2 values expected during the DCE time course. This
phantom was then used to set the flip angle (FA) in the high
temporal resolution (3 seconds) DCE protocol. Solutions of 6
different MnCl2 concentrations (12.5, 25, 50, 100, 200, and 400
M) were prepared in deionized water using manganese chloride tetrahydrate (MilliporeSigma, Burlington, MA). Further, 0.3
mL of each solution was transferred into separate 5-mm glass
NMR tubes, and the 6 tubes were packed together as a bundle.
The top of the bundle was placed just within the plane of the
surface coil, and data were collected from image slices perpendicular to the bundle axis. Thus, the MRI slice plane and surfacecoil plane were parallel and orthogonal to the axial orientation
of the 6-tube phantom, and all 6 tubes—as defined by the slice
plane cutting through the tubes—were at the same fixed distance
from the surface coil. The offset distance from the surface coil to
the slice plane used for the 6-tube phantom was typical of the
distance from the surface coil through the center of the PDXs
used in this study.
The temperature of the air surrounding the phantom was
regulated (37°C) using a temperature control system (SA Instruments, Stony Brook, NY); 1 hour was allowed for temperature
equilibration. The pulse-sequence parameters were those used
subsequently for in vivo DCE-MRI of PDX-bearing mice with
the exception that only a single slice was interrogated for a
single measurement at each of 18 FAs from 2° to 45°.
In a separate set of experiments, each tube was examined
individually and in quintuplicate at 37°C using a small solenoid
radiofrequency (RF) coil and standard MR spectroscopy relaxation measurement to determine T1 and T2. Parameters varied
for each sample: repetition time (TR) ⬎ 5 times the expected T1,
TI, and echo time (TE) arrayed to cover 3–5 expected decay
e-foldings. Nonlinear least-squares, monoexponential modeling
was used to estimate T1 and T2 values and the r1 and r2 relaxivities of MnCl2.
Single-Compartment Phantom. A 5-mL spherical plastic
phantom was filled with 150-M MnCl2 solution to evaluate the
inherent measurement accuracy and precision of the MRI protocols used herein. This concentration was chosen, based on the
measured relaxivities (r1 and r2) of Mn2⫹ determined herein, to
broadly mimic that of in vivo PDX. The temperature of air
surrounding the phantom was controlled (37°C), as described
earlier. The pulse-sequence parameters were those used subsequently for in vivo scanning of PDX-bearing mice (ie, same slice
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Figure 1. Sketch of animal positioning: Each
patient-derived xenograft (PDX)-bearing mouse
was placed on its side in a half-cylinder cradle.
Respiratory motion–induced artifacts were minimized with (i) a ridged plastic panel (10) and (ii)
judicious use of tape at locations above and below the tumor (dashed lines) and applied very
lightly over the tumor (dotted lines). The tape over
the mouse body also secured the ridged plastic
panel in place. The surface-coil receiver was
placed immediately above the tumor (8).

thickness, multiple slices through the phantom in a field of view
(FOV) approximating the typical PDX location). Analysis used a
1-mL region of interest (ROI) manually drawn in a region immediately below the surface coil, anticipating and mimicking
PDX versus surface-coil positioning. The signal-to-noise ratio
(SNR) was nominally in the same range encountered herein with
PDX in vivo. T1, T2, and ADC measurements were repeated in
quintuplicate, with the phantom removed from and repositioned
within the scanner after each measurement set.
In Vivo MRI of PDX-Bearing Mice

Mice were maintained on a temperature-controlled warm-water
pad and anesthetized with isoflurane/O2 (1.2%–1.5% isoflurane)
throughout the experiment. Within the scanner, the mice were
positioned on their sides in a 2.2-cm-inner-diameter half-cylinder cradle to allow the tumor, facing up, to be located immediately under the surface coil. Tape and a modified ridged plastic
panel (10) were placed judiciously to isolate the diaphragm and
restrict respiratory motion to the chest area, away from the
tumor and lower abdomen. Figure 1 shows a sketch of the
experimental setup. Figure 2 compares representative DCE timecourse data (single-slice tumor ROI averaged) in the absence and
presence of respiratory motion constraints. Respiratory rate and
body temperature (rectal probe) were monitored, and core temperature was regulated (37°C) with a small-animal physiologic
monitoring and control unit (SA Instruments), which was also
used for respiratory gating.
For all protocols except DCE, the initial “test” portion of the
protocol was performed in the morning of a given day, and the
second “retest” portion of the protocol was performed in the
afternoon of the same day (n ⫽ 13). Typically, the interval
between test and retest portions of the protocol was 3– 4 h,
during which time, each mouse was returned to its cage and
allowed access to food and water ad libitum. For the test–retest
DCE protocol, the initial “test” portion of the protocol was
322

Figure 2. Representative examples comparing a
dynamic contrast-enhanced (DCE) time course (2D
slice, tumor region of interest [ROI] averaged) in
the absence (A) and presence (B) of good motion
control.

performed in the afternoon of a given day following the retest
T1-, T2-, and ADC-map data acquisitions, and the second “retest” portion of the DCE protocol was performed the following
morning, allowing time for washout and excretion of contrast
agent (n ⫽ 4). Typically, the interval between the test and retest
portions of the DCE protocol was 16 –20 h, during which time,
each mouse was returned to its cage and allowed access to food
and water ad libitum. In aggregate, these test–retest scanning
sessions were conducted over a 4-month period.
Setting up the mouse in the scanner and acquiring scout,
T1W, and T2W images took ⬃15 minutes. During this time, the
animal’s core temperature stabilized at the desired 37°C target. A
schematic of the overall image acquisition pipeline including
DCE is shown in Figure 3, and pulse sequence parameters are
given below and summarized in Table 1.
T1W and T2W images were acquired at identical resolution:
matrix size ⫽ 128 ⫻ 128, FOV ⫽ 25.6 ⫻ 25.6 mm2, slice
thickness ⫽ 1 mm, number of transaxial slices ⫽ 15. Following
T1W and T2W anatomic scanning, quantitative T1-, T2-, ADCmaps and a DCE time series of images were acquired using a
reduced matrix size, 64 ⫻ 64.
T2W and T1W Images. T1W images were collected with a 2D
gradient-echo multislice sequence: TR ⫽ 100 milliseconds, TE ⫽
2 milliseconds, averages ⫽ 4; FA ⫽ 30°, data-acquisition time ⫽
52 seconds. T2W images with and without fat saturation were
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Data Analysis

Figure 3. Magnetic resonance imaging (MRI)
Data Acquisition Pipeline. The quantitative multiparameter protocol (tumor volume, T1- T2-, and
apparent diffusion coefficient [ADC]-maps, and
DCE) was designed to take ⬃1 hour per subject.
Pulse sequence parameters are listed in the text
and Table 1. The DCE protocol was only performed on an n ⫽ 4 subset of the n ⫽ 13 test–
retest cohort.

collected with a 2D fast-spin-echo multislice sequence: echo
train length (ETL) ⫽ 4, TR ⫽ 2 seconds, effective TE ⫽ 52
milliseconds, averages ⫽ 4, 90° fat saturation RF pulse ⫽ 6
milliseconds, data-collection time ⫽ 4 minutes 32 seconds each.
T1 and T2 Maps. T1 mapping used a variable flip angle, 2D
gradient-echo pulse sequence: FA ⫽ 5°, 10°, 15°, 30°, and 50°;
TR ⫽ 50 milliseconds; TE ⫽ 1.6 milliseconds; averages ⫽ 8;
data-collection time ⫽ 2 minutes 8 seconds. T2 mapping used a
multispin-echo, multislice pulse sequence: TR ⫽ 6 seconds, TE
⫽ 16 milliseconds, ⌬TE ⫽ 16 milliseconds, echoes ⫽ 16, average
⫽ 1, data-acquisition time ⫽ 7 minutes 12 seconds.
ADC Maps. ADC mapping used a respiratory-gated, spinecho, multislice sequence: TR ⫽ 1.0 seconds, TE ⫽ 23 milliseconds, averages ⫽ 2, ␦ ⫽ 3 milliseconds, ⌬ ⫽ 15 milliseconds,
b-value ⫽ 850 s/mm2, orthogonal b-vector directions ⫽ 3, and
b ⫽ 0. Total ADC-map data-acquisition time, which is dependent on respiratory rate, was ⬃12 minutes.
DCE MRI. DCE time-series data (preliminary, 4 test–retest
pairs) were collected with a gradient-echo multislice pulse sequence: TR ⫽ 47 milliseconds, TE ⫽ 1.4 milliseconds, FA 35°,
temporal resolution ⫽ 3 seconds, repetitions ⫽ 300, total scan
time ⫽ 15 minutes. At 1.5 minutes after the start of the DCE
experiment, a 100-L bolus of 50% (V/V) Dotarem® (Guerbet
LLC USA, Princeton, NJ) in saline, ⬃1.25 mmole/kg body
weight, was manually administrated over 3 seconds via a tailvein catheter.

Analysis Strategies and Software. The multislice T2W images
from each mouse were used for tumor volume measurement/
segmentation with ITK-SNAP (11). ROIs were manually drawn
around each tumor, downsampled to 64 ⫻ 64, transferred to the
lower-resolution parameter maps and DCE images, and then
refined, as appropriate, using the ROI boundaries evident from
the different contrasts present in the T1, T2, and ADC maps or
DCE time course.
T1, T2, and ADC parametric maps and uncertainties were
derived with the Bayesian Toolbox (12), a data modeling software package based upon the precepts of Bayesian probability
theory (13, 14) available for free download for noncommercial
uses (http://bayesiananalysis.wustl.edu/). These analyses were
performed in 2 different ways: (1) averaging the data and modeling the combined ROI data, indicated below as ⬍ROI⬎ and (2)
modeling each voxel in the ROI independently and averaging
the parameter estimates, indicated below as ⬍Voxel⬎. Although not a focus of the test–retest studies herein, the spatial
parameter-maps (parameter distributions) can provide additional valuable insight in the case of heterogeneous tissues (eg,
large tumors with regions of central necrosis and hemorrhage
versus metabolically active rims), whereas the ⬍ROI⬎ analysis
assumes that the voxels all represent the same underlying quantity. The Bayes Toolbox “Analyze Image Pixel” package was
used for voxel-wise parameter modeling, and the “Enter Ascii
Model” package was used for ROI-averaged data modeling.
MR Signal Models. The signal models (S) used were as follows:
For T1 determination via the variable FA () method:
S() ⫽ S(Boltzmann) ⫻ (1 ⫺ exp(⫺TR ⁄ T1))
⫻ sin() ⁄ (1 ⫺ exp(⫺TR ⁄ T1)) ⫻ cos()

(1)

For T2 determination via the multispin-echo (ie, multi-TE)
method:
S(TE) ⫽ A ⫻ exp(⫺TE ⁄ T2) ⫹ Constant

(2)

For ADC determination via 3 b-vectors (bx, by, bz) and b0, the full
tensor model was used to account for the diffusion weighting of
the imaging gradients; however, the underlying free-diffusion
model, equation (3), is valid for tissue water within the Gaussian
phase approximation regime (15):

Table 1. Pulse Sequences and Parameters
VnmrJ-4.2A:
Pulse
Sequence

MRI

2D Slice
Matrix
Size

Averages

TR
(ms)

TE
(ms)

ETL (Echo
Train
Length)

Flip
Angle
(FA)

T1W

Gradient Echo Multislice

128 ⫻ 128

4

100

2

–

30°

T2W

Fast Spin Echo Multislice

128 ⫻ 128

4

2000

52

4

–

T2W with Fat Sat

Fast Spin Echo Multislice

128 ⫻ 128

4

2000

52

4

–

T2-Map

Multiecho Multislice

64 ⫻ 64

1

6000

–

–

ADC

Spin Echo Multislice

64 ⫻ 64

2

1000

–

–

T1-Map

Gradient Echo Multislice VFA

64 ⫻ 64

8

50

1.6

–

5°, 10°, 15°,
30°, 50°

DCE

Gradient Echo Multislice

64 ⫻ 64

1

47

1.4

–

35°
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Table 2. Single-Compartment Phantom Test–Retest Variability
Parameter

Spectroscopy True Value

a

T1⬍ROI⬎, s

T1⬍Voxel⬎, s

b

T2⬍ROI⬎, msa
T2⬍Voxel⬎, msb
ADC⬍ROI⬎, m2/msa
ADC⬍Voxel⬎, m2/msb
b

0.921 ⫾ 0.04
54 ⫾ 3
3.1 ⫾ 0.1

Mean

SD

CV (%)

Bias (%)

0.85

0.02

2.6

⫺7.8

0.86

⫺6.7

0.03

3.4

52.1

1.9

3.7

⫺2.6

52.2

1.9

3.5

⫺2.8

3.0

0.1

3.9

⫺1

3.0

0.1

3.9

⫺3.3

a
<ROI>: Results from modeling averaged data from the entire phantom ROI over all five measurement repeats.
⬍Voxel⬎: Results from modeling each phantom voxel independently and summarized over the five measurement repeats.

S(b) ⫽ S(b ⫽ 0) ⫻ exp(⫺b ⫻ ADC).
(3)
These signal models all share an underlying exponential character. The interested reader will find additional insight regarding
Bayesian analysis of exponentially decaying signals in (16-20).
Although the DCE findings must be regarded as preliminary
owing to the small number of paired test–retest determinations
(n ⫽ 2 ⫻ 4), each signal time-course was quantified by 2
metrics: (1) the contrast agent extravasation rate constant,
Ktrans, derived via the 3-parameter (Ktrans, Ve, Vp), 2-compartment exchange model, often referred to as the extended or
modified Tofts model (21-26) and (2) the area under the timecourse curve (AUC). For compartmental exchange modeling, the
arterial input function was approximated using the reference
region (RR) approach (27-30) in which muscle is chosen as the
RR with fixed extended Tofts model parameters: RR Ktrans ⫽
0.02 min⫺1 (31), RR Ve ⫽ 0.08 (31-33), and RR Vp ⫽ 0.02 (33).
The underlying RR assumption is that muscle is well perfused,
homogeneous, and responds identically to contrast agent on an
exam-to-exam and mouse-to-mouse basis. Contrast agent relaxivity was assigned as 5.8 mM⫺1s⫺1, vide infra. Modeling
(fitting the data) used the variable projection (VARPRO) formulation of the maximum likelihood parameter estimation approach (34).
The area under the DCE time-course curve (DCE-AUC) following contrast agent injection was calculated on a voxel-wise
basis as follows. At each time point, the signal was expressed as
the fractional enhancement in voxel intensity relative to the
precontrast period, to account for signal variations between
scans. To account for potential modest variations in the contrast
agent injection, the signal was further normalized by the maximum fractional enhancement in the early time frames (n ⫽
31-120) of the lateral dorsal (lumbosacral caudal) muscle in the
5 slices covering the central portion of the tumor. The AUC was
expressed on a per-unit-time (s) basis by dividing the sum of the
normalized signal over the postinjection frames by 810 (3
s/frame ⫻ 270 postinjection frames) and, in this sense, can be
considered equal to the mean signal enhancement over the
postinjection time window.
Statistical Analysis. Standard statistical analysis—means,
medians, standard deviations (SDs), coefficients-of-variation
(CVs), Bland–Altman plots— of MR-derived parameters was performed using Matlab (MathWorks, Natick, MA) and Excel (Microsoft, Redmond, WA).
As noted by Hyslop and White in their report on estimating
precision using duplicate measurements (35): “Precision is a
concept for which there is no universally accepted metric. Reports of precision vary depending on the formula and inclusion
324

criteria used to calculate them.” Herein, we wish to express the
variability in duplicate (ie, test–retest) measurement pairs.
Therefore, in addition to Bland–Altman plots (36, 37), we provide the within-subject SD (SDws) (38) and the within-subject CV
(CVWS) (35), that is, the root-mean-square of the scaled relative
differences. In assessing test–retest results for a given MRIdetermined parameter, the absolute value of the difference between 2 paired repeat determinations is indicated by the symbol
⌬. The within-subject standard deviation and CVWS are then
given by equations (3) and (4):
SDWS ⫽ [(⌺⌬2)/2n]1⁄2 ,

(4)

where the sum is taken over the number of test–retest paired
duplicate measurements (n), and
CVWS(%) ⫽ 100 ⫻ ([⌺(⌬/m)2]/2n)1⁄2 ,

(5)

in which m is the mean of the 2 paired repeat determinations
whose absolute difference is ⌬, and the sum is taken over the n
test–retest paired duplicate measurements.
The width of each voxel-wise parameter distribution is summarized as the “SD of the parameter distribution.” In this case, ⌬
for the distribution width test–retest (the difference between the
standard deviations of the voxel-wise parameter distributions) is
indicated by the symbol ⌬DW.
In addition to metrics quantifying precision, assessing test–retest bias (significant difference from zero) is also of interest (Bland–Altman plots, vide infra). The 95% confidence
interval for mean test–retest difference ⬍d⬎ was assigned as
⬍d⬎ ⫾ (t ⫻ SEM) where t is the value of the t distribution
with n ⫺ 1 degrees of freedom and SEM is the standard error
of ⬍d⬎ (36, 37).
RESULTS
Phantoms

Protocol Assessment via Single-Compartment Phantom
Sample. As expected, even with removal and repositioning of
the phantom between measurements, the parameter variability
across consecutive determinations of T1, T2, and ADC in the
single-compartment homogeneous phantom was small
(Table 2). CVs for ⬍ROI⬎ parameter values (n ⫽ 5) were 2.6, 3.7,
and 3.9% for T1, T2, and ADC, respectively. Similar mean, SD,
and CV values resulted from ⬍ROI⬎ and ⬍Voxel⬎ analysis. As
will be seen, the phantom T1 and ADC CVs, whether ⬍ROI⬎ or
⬍Voxel⬎ based, are smaller (⬃1.5 to 4.2⫻) than those obtained
for PDX in vivo, while the phantom T2 CVs are somewhat larger
(⬃1.4⫻) than observed for PDX in vivo.
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Table 3. T1 and T2 Determinations with the 6-Compartment Variable Relaxation Phantom
MnCl2 Sample
Concentration

IR MRSa

VFA (5 FA)
<Voxel>b

VFA (18 FA)
<Voxel>b

SE MRSc

ME 16 TEs ⴛ 16 ms
<Voxel>d

mM

Mean T1,
s, (SD) n ⴝ 5

Mean T1,
s, (SD)

Mean T1,
s, (SD)

Mean T2,
ms, (SD) n ⴝ 5

Mean T2,
ms, (SD)

0.0125

3.63 (0.01)

3.1 (0.5)

3.2 (0.3)

483 (2)

250 (30)

0.025

2.74 (0.01)

2.6 (0.3)

2.6 (0.2)

281 (3)

210 (20)

0.050

2.14 (0.01)

2.0 (0.2)

2.0 (0.1)

189 (6)

140 (9)

0.10

1.75 (0.01)

1.2 (0.1)

1.2 (0.1)

113 (2)

79 (4)

0.20

0.744 (0.003)

0.77 (0.07)

0.75 (0.04)

41.0 (0.4)

45 (3)

0.40

0.399 (0.005)

0.42 (0.03)

0.41 (0.02)

15.0 (0.3)

23 (2)

a

Inversion-recovery (IR) MR spectroscopy (MRS) measurements of T1.
Variable flip angle (VFA) T1 measurements across all phantom voxels with either 5 or 18 flip angles (FA).
c
Spin-echo (SE) MRS measurements of T2.
d
Multi-(Spin)-echo (ME) measurements of T2 across all phantom voxels.
b

In addition to measurement precision, phantom samples offer
an opportunity to assess accuracy (bias). MR spectroscopy–
based measurements in the absence of imaging gradients provided “true value” determinations of T1, T2, and ADC for the
single-compartment homogeneous phantom. The image-based
determinations were within 8%, 3%, and 3% of the true value
determinations for T1, T2, and ADC, respectively.
Six-Compartment Variable Relaxation Phantom. The 6-compartment phantom contained homogeneous compartments,
with T1 and T2 values bridging the expected range encountered
for various tissues and over the DCE time course (Table 3).
Aqueous Mn2⫹ relaxivities (r1, r2) derived from these data
(201.5 MHz; 37°C) via equation (5) were r1 ⫽ 5.8 ⫾ 0.3 mM⫺1s⫺1
(R2 ⫽ 0.99) and r2 ⫽ 166 ⫾ 14 mM⫺1s⫺1 (R2 ⫽ 0.98).
R1,2([Mn2⫹]) ⫽ R1,2([Mn2⫹] ⫽ 0) ⫹ r1,2 ⫻ [Mn2⫹]

(6)

Using the DCE pulse-sequence parameters, the FA was varied to
map signal (contrast) changes between compartments with differing T1 in the 6-compartment phantom. Conceptually, for an
anticipated range (dynamic) of T1s, selection of the “optimal”
FA will depend upon 2 competing/opposing considerations,
with a desire to obtain: (1) the greatest T1-dependent signal
amplitudes (ie, SNR) and (2) the greatest difference in T1-dependent signal amplitudes (ie, image contrast) for tissues with
different T1s. Thus, the optimal/ideal FA would provide (1)
maximal signal (tissue detectability) and (2) maximal tissue
contrast (tissue differentiation) between tissues with different
DCE time-course profiles. (We recognize that the dynamics of
the time course itself provide a second contrast mechanism.) We
qualitatively weighted these 2 factors equally for T1 values most
representative of what would be anticipated for the various
tissues in the FOV during the DCE time course. Although the
region of optimality is rather broad, a nominal FA of 35° was
selected for the in vivo PDX DCE protocol. This choice is at
the upper end of the 25°–35° FA range recommended by
the Quantitative Imaging Biomarkers Alliance (QIBA), but
herein a contrast agent dose is leveraged that is substantially
greater (⬃10⫻) than QIBA suggests for clinical studies (39)
(Figure 4).

in Figure 5 for a single transaxial slice through the center of the
tumor for a single mouse. Characteristics of the entire cohort are
summarized in Table 4. Citing parameter ⬍ROI⬎ values, which
were similar to parameter ⬍Voxel⬎ values, tumor volume
ranged from 31 to 318 L with a mean ⫾ SD of 174 ⫾ 73 L; T1
ranged from 1.4 to 2.3 seconds with a mean of 1.9 ⫾ 0.2
seconds; T2 ranged from 56 to 68 milliseconds with a mean of
62 ⫾ 3 milliseconds; ADC ranged from 0.59 to 0.83 m2/ms
with a mean of 0.71 ⫾ 0.06 m2/ms; DCE-Ktrans ranged from
0.01 to 0.06 min⫺1 with a mean of 0.025 ⫾ 0.015 min⫺1; and
DCE-AUC ranged from 0.18 to 1.4 au with a mean of 0.77 ⫾ 0.30
au.
Dependence of MRI-Determined Parameters on PDX Volume.
Small-animal tumor models often use tumors in the 1- to 2-cm
range. Approximating the tumor as a sphere of water, a 1-cmdiameter tumor would have a volume of 0.52 mL or ⬃2.6% by
weight of a 20-g mouse; a 2-cm-diameter tumor would have a
volume of 4.2 mL or ⬃20% by weight of a 20-g mouse. Such

In Vivo TNBC PDX MRI

PDX Cohort MRI-Determined Parameter Summary. Representative parameter maps for T1, T2, ADC, and DCE-AUC are shown
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Figure 4. Exploring DCE with the 6-compartment
relaxation phantom. Plots of the signal intensity of
each tube as a function of flip angle (FA). The T1
values (Table 3) were chosen to bridge the expected range for tissues in vivo and during the
DCE experiment.
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Figure 5. Representative PDX T2weighted (T2W) images and magnetic resonance (MR) parametric
maps. T2W (A), T2W-FatSat (B),
T1 (C), T2 (D), ADC (E), and DCEAUC (F) parametric maps from a
single central slice through a
206-L tumor. T2W image intensity
scaling is arbitrary. Parametric map
intensities are given by vertical
scale bars. The tumor is outlined
with a yellow line. Isolated white or
black voxels (specks) generally occur in anatomic regions of very low
signal-to-noise ratio (SNR) under the
protocol conditions and thus reflect
a modeling (parameter estimation)
failure. The hyperintense T2W fat
signal is a known artifact of the fast
spin-echo (FSE) protocol (45-47).

“large” tumors in small-animal models are often quite heterogeneous, with substantially necrotic and hemorrhagic centers
and rims that remain metabolically active with continued
growth. These characteristics are not generally representative of
human breast tumors diagnosed in the clinic, where TNBC most
commonly presents as a mass on mammography, most frequently round, oval, or lobular in shape, with indistinct margins,
and no associated microcalcifications, irregular spiculated
masses, or pleomorphic microcalcifications (40). The tumors

used for the test–retest studies herein averaged 0.174 ⫾ 0.073
mL in volume, representing ⬍1% of the mouse’s weight (⬃20 g).
We note in passing that size comparisons are relative. Human
female breast tumors range from barely detectable to 5 cm and
larger. Typical human female breast volume is ⬃550 mL,
roughly a pound. Approximating the tumor as a perfect sphere
of water, a 5-cm tumor would have a volume of 65 mL or 12%
of the typical human breast volume or weight. The weight of the
mouse fourth inguinal fat pad is ⬃50 ⫾ 10 mg (mean ⫾ SD, n ⫽

Table 4. PDX Cohort MRI-Determined Parameter Summary
Parameter

Mean

Median

SD

Range

Volume, L

174

177

73

31–318

Volume, L, for DCE subset

235

249

62

145–299

T1 ⬍ROI⬎, sa

1.86

T1 ⬍Voxel⬎, s

b

1.92

1.88

0.22

1.4–2.3

1.93

0.24

1.4–2.4

T2 ⬍ROI⬎, msa

62

61

3.0

56–68

T2⬍Voxel⬎, msb

62

62

7.4

56–68

ADC⬍ROI⬎, m /ms

0.71

0.71

0.06

0.59–0.83

ADC⬍Voxel⬎, m2/msb

0.73

0.73

0.08

0.59–0.88

DCE-AUC⬍ROI⬎, aua

0.77

0.30

0.18–1.4

0.30

0.18–1.4

0.015

0.01–0.06

0.031

0.00–0.10

2

a

b

DCE-AUC⬍Voxel⬎, au

0.77

DCE-Ktrans ⬍ROI⬎, min⫺1 a

0.025

trans

DCE-K

⬍Voxel⬎, min

⫺1 b

0.035

–
0.70
–
0.027

The test and retest measurements were averaged and are summarized over all mice (n ⫽ 13 for T1, T2, ADC; or n ⫽ 4 for DCE-AUC, DCE-Ktrans).
⬍ROI⬎ measurements from modeling the averaged data over the entire tumor volume.
c
⬍Voxel⬎ measurements from modeling each tumor voxel independently, averaging across repeats, and summarized across all animals.
a

b
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Table 5. PDX Cohort MRI-Determined Parameter Test–Retest Within-Subject Variability
Mean ⌬a

Parameter

SDWS ⌬a

Mean ⌬DWb

SDWS ⌬DWb

CVWS ⌬a (%)

CVWS ⌬DWb (%)

Volume, L

1.7

1.5

–

–

T1⬍ROI⬎, s

0.24

0.21

–

–

T1⬍Voxel⬎, s

0.18

0.16

0.05

8.6

22

T2⬍ROI⬎, ms

1.8

1.6

–

–

2.6

–

1.7

1.6

2.5

20

–

–

7.0

–

0.03

5.8

16

0.06

0.94
11

–
–

T2⬍Voxel⬎, ms

1.8

1.6

ADC⬍ROI⬎, m2/ms

0.05

0.05

ADC⬍Voxel⬎, m2/ms

0.05

0.04

DCE-AUC⬍ROI⬎, au

0.17

0.17

DCE-AUC⬍Voxel⬎, au

0.17

0.17

DCE-Ktrans⬍ROI⬎, min⫺1

0.012

0.013

–

–

32

–

DCE-Ktrans⬍Voxel⬎, min⫺1

0.017

0.016

0.012

0.01

44

28

0.03
–
0.15

–

29

–

0.11

29

33

a
The symbol ⌬ indicates the absolute value of the difference between two paired repeat determinations.
The width of each voxel-wise parameter distribution is summarized as the SD of the parameter distribution. In this case, ⌬ for the distribution width
test-retest is indicated as ⌬DW.
b

4). Thus, although only 30 L (⬃30 mg) of TNBC cells was
implanted into the mouse mammary fat pad, the tumors used in
our report had grown to a mean weight corresponding to 3.5⫻
the mammary fat pad weight.
The dependence of MR parameters on PDX volume over the
range of volumes examined (31–318 L) was minimal and
generally not statistically significant. There are only 2 statistically significant trends with increasing PDX volume: (1)
T1⬍Voxel⬎ showed a small decrease (⫺0.002 s/L), as did (2)
the voxel-wise T1 distribution width, as given by T1CV⬍Voxel⬎ (⫺0.03%/L). Whether the weak dependence of
these parameters on PDX volume reflects physiologic or microenvironment changes as tumors grow is unclear. The dependency may simply reflect the greater measurement precision/
accuracy afforded by larger tumor volumes.
PDX MRI-Determined Parameter Test–Retest Variability

Test–retest variability in MRI-determined parameters is summarized in Table 5. Further assessment of DCE test–retest variability was not undertaken owing to the small number of paired DCE

measurements (n ⫽ 4 ⫻ 2) and the substantial CVWS observed,
the genesis of which remains to be ascertained.
Figure 6 shows the full ROI test–retest T1-, T2-, and ADCnormalized voxel-wise distribution plots for the tumor displayed in Figure 5. The degree of test–retest voxel-wise distribution congruence shown is broadly representative of all 13
test–retest T1, T2, and ADC determinations. Bland–Altman plots
(36, 37) are shown in Figure 7 for tumor volume and T1, T2, and
ADC ⬍ROI⬎ means and in Figure 8 for voxel-wise distribution
widths (voxel-wise SDs).
As anticipated, there is good concordance between tumor
⬍ROI⬎ and ⬍Voxel⬎ parameter mean test–retest results. Test–
retest CVWS values are the smallest for tumor-volume determination, ⬃1%, and then scale as T2 ⬍ ADC ⬃ T1 ⬍⬍ DCE-AUC
and DCE-Ktrans. Clearly, the DCE-AUC and DCE-Ktrans test–
retest determinations showed the greatest variation of all the
MRI parameter determinations, with CVWS in the 30%– 40%
range.

Figure 6. Representative PDX
test–retest full ROI-normalized
voxel distribution plots. For the
same 206-L tumor shown in Figure 5, the test–retest-normalized
voxel distributions for maps of T1
(A), T2 (B), and ADC (C) are
overlaid to provide a visual representation of measurement reproducibility. Quantitative test–retest
summary statistics for the entire
cohort are listed in Table 5.
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Figure 7. Bland–Altman plots for
the test–retest cohort ⬍ROI⬎
Analysis. The ⬍ROI⬎-determined
mean of test and retest parameter
values (x-axis) and difference in
test and retest parameter values
(y-axis) are shown for each tumor
(volume (A), T1 (B), T2 (C), ADC
(D)), together with overall mean of
the test–retest differences (green
lines) and 95% confidence limits
(red and blue lines). Apparent
biases were not statistically significant (P ⬎ .05).

DISCUSSION
Longitudinal monitoring of quantitative MRI parameter summary statistics (and, ultimately, voxel-wise distribution characteristics) as indices for predicting and assessing tumor therapeutic response requires knowledge of the test–retest precision of
such metrics. In the clinic, initiating and modifying therapeutic
intervention based on MRI metrics require knowledge of when
an observed change in an MRI parameter(s) is likely to be
significant. Supported through the National Cancer Institute
Co-Clinical Imaging Resource Program initiative, this work is
the first step toward such assessment with TNBC PDXs implanted in abdominal mammary fat pads. The measurement is
challenged by the SNR achievable in a ⬃60-minute multicontrast scanning protocol and by residual subject respiratory motion.
Herein, to suppress respiratory motion, several strategies
have been used, including: (1) a half-cylindrical mouse cradle
whose inner diameter is optimized for a snug fit with the mouse
lying on its side, (2) a modified ridged plastic panel (10) to
restrict respiratory motion to the chest area, away from the
lower abdomen, (3) a judicious use of body taping to reduce
residual motion (see Figure 1), and (4) for ADC mapping, where
sensitivity to motion is extreme, respiratory gating of the data
collection. The 2D slice-selective DCE protocol is particularly
sensitive to motion, resulting in slice positional changes that
disrupt the steady-state magnetization condition. This is graphically illustrated in Figure 2 for the cases of poor versus good
motion control as achieved herein.
Obtaining sufficiently high SNR and spatial resolution is
always challenging in MR imaging of mice, whose body volume
is ⬃3,000-fold less than that of the adult human. Although high
magnetic fields and small-diameter RF receiver coils improve
sensitivity, one is always faced with decisions regarding the
trade-off of SNR versus spatial resolution versus data-acquisition scan time. Because our PDX-bearing mice experience unavoidable physiological stress, including therapy and repeated
anesthesia and handling for MRI scanning, a 1-hour multicon328

trast scanning protocol was developed to provide sufficient
throughput, SNR, and spatial resolution, while minimizing time
under anesthesia. In addition, it was recognized that on a modern preclinical MRI scanner, image analysis often poses the more
time-consuming component. Thus, to maximize throughput,
standard multislice, Cartesian k-space-encoding pulse sequence
protocols were used.
The range of FA and TE parameters used to collect the T1
and T2 data in the 2 phantoms was the same as used for the
PDXs. The multiecho T2 measurement is time-efficient, and
thus, the number of echoes (TE ⫽ ⬃16 milliseconds) was set at
16 to quantify tissues with long T2 values (eg, bladder) in the
FOV. The variable FA T1 measurement is not as time-efficient.
The use of 5 FAs was found to provide moderately decreased,
though sufficient, precision in T1 determination compared with
the use of 18 FAs. As expected, the multiecho T2 measurement
was the most accurate and precise when multiple e-foldings of
the signal decay were captured by multiple echoes. At the
extremes of long and short T2s examined in the 6-compartment
phantom, the multiecho pulse sequence parameters that were
used for in vivo PDX were far from optimal.
Tumor MRI parameter determinations showed different test–retest sensitivities to inevitable protocol nonidealities. T2W
anatomical scanning is time-efficient and provides high spatial
resolution and good tumor-to-background contrast. Thus, tumor volume determination via multislice T2W MRI was highly
robust, with a ⬃1% test–retest CVWS. T2-map determination
using a multislice, multiecho protocol is also time-efficient and
relatively insensitive to modest imperfections in pulse and
transmit RF-fields. Thus, T2-map determinations were also robust, with a ⬃3% test–retest CVWS (mean value over the tumor
volume). The variable FA T1-map determination is sensitive to
transmit RF-field imperfections, which results in a nonuniform
FA over the FOV, and it suffers from limited dynamic range and
SNR relative to more time-consuming (eg, inversion recovery)
T1 protocols. In principle, the effect of transmit RF field imperfections can be mitigated by including a B1-field mapping

TOMOGRAPHY.ORG

|

VOLUME 5

NUMBER 3

|

SEPTEMBER 2019

Multiparametric MRI Test–Retest Reproducibility With TNBC PDX

Figure 8. Bland–Altman plots for the test–retest
cohort ⬍Voxel⬎ analysis. The voxel-wise-determined mean of test and retest parameter values
(x-axis) and difference in test and retest parameter
values (y-axis) are shown for each tumor (T1 (A),
T2 (B), ADC (C)), together with the overall mean
of the test–retest differences (green lines) and 95%
confidence limits (red and blue lines). Apparent
biases were not statistically significant (P ⬎ .05).

protocol. This was not done herein because a transmit volume
coil was used that produced a relatively homogeneous B1 field
over the tumor volume. Nevertheless, despite these sensitivities
to protocol imperfections, the T1-map determination was relatively robust, with a ⬃9%–11% CVWS (mean value over the
tumor volume).
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The ADC map determination is sensitive to respiratory motion and the limited SNR at high b-values. Using lower b-values
provides higher SNR at the expense of reduced dynamic range.
Bito et al. (41) showed that the optimal b-value for a single ADC
is that which results in ⬃1 e-folding in the diffusion signal
decay (ADC ⫻ b-value ⫽ ⬃ 1). However, tissue ADC values
vary depending upon tissue characteristics. Thus, providing
good-quality ADC-map contrast between the PDX and surrounding abdominal tissues with different ADC values is also
desired. Koc and Erbay (42) evaluated optimal b-values for
differentiation of abdominal lesions and recommended values of 600 s/mm2 or higher. We anticipate animals in the
second part of the coclinical trial, which will monitor PDX
growth and therapeutic response, will ultimately be bearing
substantially larger PDX with fluid-enriched necrotic regions
(higher ADCs). Thus, we qualitatively chose a b-value of 850
s/mm2, somewhat higher than the recommended 600 s/mm2,
to bridge between the ADCs for the more cellular-dense
versus necrotic fluid-rich tissues. The resulting ADC maps
showed a ⬃6%–7% CVWS (mean value over the tumor volume).
The DCE protocol used herein was designed to provide
strong DCE signal under high temporal resolution (3-second
frames). In early exploratory studies, it was found that low doses
of contrast agent provided low DCE SNR. The dose was adjusted
to provide high DCE SNR, but not such a large dose as to induce
DSC-like T2* effects with the short echo time (⬃1.6 milliseconds) used. At the dose used, a strong muscle DCE signal was
observed, useful for normalization regarding AUC and RR AIF
estimation regarding Ktrans, and no apparent, frank effects on
renal contrast agent clearance and vascular function were observed. Specifically, the “DCE signal” was near baseline at 1–2 h
post administration.
While DCE findings should be considered preliminary owing to the small number of paired test–retest determinations, by
far the least robust were the DCE-AUC and DCE-Ktrans determinations, yielding ⬃30%– 40% CVWS. The reason for this is unclear, but substantial DCE variability is a common finding (39,
43, 44). It seems unlikely that significant residual contrast agent
remained in the tumor following the ⬃16- to 20-h period between the paired test–retest determination, as the T1-maps did
not show substantive test–retest bias. The DCE paired test–retest
determination was carried out in the afternoon versus morning
of consecutive days, and it is possible that animals were in
different metabolic/physiologic states related to their normal
diurnal cycle. No attempt was made to control for this. Contrast
agent was administered via manual injection into the tail vein
through catheters that were placed by a highly experienced
small-animal procedure technologist. While a power injector
might improve somewhat on within-animal bolus uniformity,
the injected volumes were small and not highly variable. Further, the tumor DCE-AUC normalization to the maximum muscle DCE enhancement in the early time frames and the reference
RR AIF estimation regarding Ktrans should have substantially
mitigated effects of injection variability. Thus, while the genesis
of the large CVWS observed with tumor DCE determinations
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remains unclear, it does motivate additional experiments with
control-state (nontumor bearing) mice, and this will be the
subject of future investigations.
CONCLUSION
Determination of PDX volume via manually drawn ROIs is
highly robust, with a ⬃1% test–retest CVWS. Mean T2 is also
a robust determination, with a ⬃3% test–retest CVWS. Mean

T1 and ADC are less robust, with test–retest CVWS in the
⬃6%–11% range. The least robust, in a test–retest sense, are
the DCE-AUC and DCE-Ktrans, with test–retest CVWS in the
⬃30%– 40% range.
Ongoing work will assess methods to further quantify the
shape/character of the voxel-wise parameter distributions (ie,
methods of histogram analysis) and the robustness of these
measures to test–retest evaluation.
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